Table HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) [see all tables in this series...]

Part (ii) Estimates and share of clients in methadone (MMT) and high-dosage buprenorphine (HDBT) treatment in EU-27, Croatia, Turkey and Norway in 2008

Country		Number of MMT clients	MMT share		Number of HDBT clients	HDBT share		All substitution clients
Belgium		:	:		:	:		:
Bulgaria		2863	88		0	0		3238	(1)
Czech Republic		705	18		3280	82		3985	(2)
Denmark		7100	88		950	12		8050	(17)
Germany		57976	80.3		13645	18.9		72200	(3)
Estonia		1008	100		0	0		1008
Ireland		10213	100		0	0		10213
Greece		2838	56		2215	44		5053
Spain		:	:		0	0		:
France		33565	26		97116	74		130681
Italy		83481	86		14027	14		97509	(16)
Cyprus		0	0		58	100		58
Latvia		103	63		61	37		164	(5)
Lithuania		640	76		198	24		838
Luxembourg		:	95		:	4		1050	(6)
Hungary		683	85		0	0		802	(7)
Malta		:	:		:	:		:
Netherlands		:	:		:	:		:
Austria		:	32		:	32		11119	(8)
Poland		1522	100		0	0		1522	(9)
Portugal		:	75		:	25		25808	(10)
Romania		:	:		0	0		:
Slovenia		2515	75		555	17		3332	(11)
Slovakia		480	80		0	0		600	(12)
Finland		516	43		660	55		1200	(13)
Sweden		:	:		:	:		:
UK- England		120889	81		:	:		149986	(14)
UK-Scotland		:	:		:	:		:
UK-Northern Irel.		:	:		:	:		550
Croatia		877	38		1430	62		2307
Turkey		0	0		0	0		0
Norway		2949	60		1966	40		4915	(15)

Notes:

 Where data are not available for a country, the table entry is left empty. 

 Substitution treatment programmes are not available in Turkey. 

 Where possible, data on clients receiving the buprenorphine-naloxone combination are presented separately.                   

 For further information on client population covered, estimation processes and other notes by country see part (iii).  

 (1) The number of "All substitution clients" in Bulgaria includes 375 slow-release morphine clients (12%). On 31 December 2008, there were 2382 clients receiving opioid substiution treatment, 2143 clients receiving methadone and 239 receiving slow-release morphine. 

 (2) The number of buprenorphine clients in the Czech Republic is estimated based on the distributed quantity of HDB on the Czech market (in 2008, a quantity of Subutex® and Suboxone® equivalent to 3.595 g) and the avarage daily dose (6 mg of buprenorphine and a bi-daily average frequency of administration).  

 (3) The number of "All substitution clients" in Germany includes 579 clients divided between 361 codeine and 218 diamorphine. 

 (5) Based on a census conducted on the 31 December 2008, thus the total number of clients treated during the year is estimated to be higher. 

 (6) The shares are calculated from prescriptions, while not client-based on share is not available. Also based on prescriptions, 1% of all clients are prescribed the combination buprenorphine-naloxone. 

 (7) The number of "All substitution clients" in Hungary includes 119 clients receiving the buprenorphine/naloxone combination. 

 (8) Valid data on the share between substances in Austria are only available for clients treated for the first time in life in 2008 and not to all treatments. The remaining shares are as follows: buprenorphine-naloxone combination = 10%, SRM = 25% and Codeine = 1%. 

 (9) Based on a census conducted on the 31 December 2008, thus the total number of clients treated during the year is estimated to be higher. 

 (10) Valid data on the share between substances in Portugal are available for 18.815 clients registered in opioid maintenance programs in outpatient units by IDT. On 31 December 2008, there were 14.111 clients receiving methadone and 4703 receiving buprenorphine. The number of clients in HDBT in Portugal includes clients receiving the buprenorphine/naloxone combination. 

 (11) The number of clientsin HDBT in Slovenia includes clients receiving the buprenorphine/naloxone combination. The number of "All substitution clients" includes also 262 clients in substitol (morphine sulfate pentahydrate). 

 (12) The number of "All substitution clients" in Slovakia includes 120 clients receiving buprenorphine/naloxone combination. 

 (13) There is no routine data collection in place on this matter and data is based on ad hoc reports. It is estimated that 83% of the HDBT clients have buprenorphine/naloxone combination treatment. 

 (14) Data represent the number of people being prescribed for as part of drug treatment in England. Only data for Wales is that in 2008/09 there has been 2617 referrals to OST agencies. The data on methadone clients is based on the results of a prescribing audit that found that 80.6% of clients in prescribing services received methadone. Best D and Campbell A (2006) Summary of the NTA's national prescribing audit. NTA Research Briefing 19, June 2006. .  

 (15) The shares are based on reports from the 14 region regional centres. For 2008, 4 172 forms were completed, 77.5 % of the total number of clients(4915). Thus, the shares represent an estimate. The number of buprenorphine clients in Norway includes clients receiving buprenorphine/naloxone combination. 

 (16) Service coverage at time of writing was 85%, thus the total number of clients is underestimated.  

 (17) The number of clients includes 300 clients on methadone from prisons and probation services.  

 See also 'General notes for interpreting data' on the Explanatory notes and help page. 

Sources:

 Reitox National Reports 2009. 

 For the UK-England data: NTA report, "Statistics from the National Drug Treatment Monitoring System (NDTMS)",17th February 2010.  

 CY: personal communication NFP 16/02/2009. 

 AT: personal communication NFP 16/02/2009. 

 FR: personal communication NFP 02/03/21010                    

 SK: personal communication NFP 25/03/21010                    

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)